SciSparc Announces Positive Study Results with SCI-210, a Cannabidiol-Based Treatment for Epilepsy
The non- clinical study was conducted at The Chaim Sheba Medical Center in Israel
Tel-Aviv, Dec. 07, 2022 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq:SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), today announced positive results from its study of SCI-210 on Status Epilepticus (“SE”), conducted at The Sheba Fund for Health Services and Research at Chaim Sheba Medical Center, which reaffirm the potential of its proprietary combination products to have a positive effect while minimizing adverse side effects. The Company’s proprietary SCI-210 platform combines Palmitoylethanolamide (“PEA”) with Cannabidiol (“CBD”).
Related news for (SPRC)
- SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders
- 24/7 Market News Snapshot 20 October, 2025 – SciSparc Ltd. Ordinary Shares (NASDAQ:SPRC)
- 24/7 Market News Snapshot 20 October, 2025 – SciSparc Ltd. Ordinary Shares (NASDAQ:SPRC)
- Today’s Top Performers: MoBot’s Market Review 10/15/25 09:00 AM
- SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio